相关实验视频
Updated: Jan 10, 2026

10:56
Assays for the Degradation of Misfolded Proteins in Cells
Published on: August 28, 2016
12.5K
蛋白质错误折叠和神经退行:机制,影响和治疗策略
Asma Shah1, Tharini Karthikeyan2, Sheema Hashem3
1Watson-Crick Centre for Molecular Medicine, Islamic University of Science and Technology, Awantipora, Kashmir, India.
Advances in protein chemistry and structural biology
|November 27, 2025
概括
蛋白质错误折叠和聚合是神经退行性疾病 (如阿尔茨海默氏症和帕金森症) 的关键驱动因素. 了解这些过程和蛋白质稳定网络为针对这些衰弱条件的多目标治疗策略提供了潜力.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 蛋白质错误折叠和聚合是神经退行性疾病的核心,包括阿尔茨海默氏症和帕金森氏症.
- 细胞功能障碍和认知能力下降是毒性蛋白质聚合物破坏正常过程的结果.
- 遗传突变,氧化应激和衰老等因素有助于蛋白质错误折叠.
研究的目的:
- 提供关于神经退行症中蛋白质错误折叠的分子机制的全面概述.
- 探索蛋白质稳定网络在缓解这些病理过程中的作用.
- 突出多目标治疗策略,并确定未来治疗的研究缺口.
主要方法:
- 对蛋白质错折和聚合背后的分子机制的审查.
- 对蛋白质稳定网络的功能和治疗相关性的分析.
- 综合关于多目标治疗方法的当前知识.
主要成果:
- 错误折叠的蛋白质形成有毒聚合物,损害细胞功能并导致神经元损伤.
- 蛋白质稳定网络在管理蛋白质折叠和降解方面发挥着至关重要的作用.
- 多目标策略显示出解决神经退行性疾病的根本原因的前景.
结论:
- 针对蛋白质错误折叠和利用蛋白质稳定网络对于开发有效的神经退行性疾病疗法至关重要.
- 对多目标治疗策略的进一步研究对于打击与蛋白质错折相关的神经退行症至关重要.
- 识别和解决研究缺口将加速对这些破坏性疾病的新型治疗方法的开发.
相关概念视频
Amyloid Fibrils
11.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.5K
Amyloid Fibrils
6.3K
6.3K
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
764
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
764
The Proteasome
1.6K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.6K

